Introduction: The main curative therapy for NET is surgical resection when the disease is localized. But high percentage of patients is diagnosed with advanced disseminated disease and the peptide receptor radionuclide therapy (PRRT) with somatostatin analogs (SSA) is an emerging effective treatment.
Aim(s): Evaluate short term effectiveness and tolerability of 177-Lutetium-DOTATATE in the metastatic or inoperable NETs in our centre.
Materials and methods: Analyse bichemical, clinical and imaging response and side effects of the therapy.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Doctor Maria Picallo
, Percovich J C
, García Centeno R
, Rotger A
, Colon A
, Peligros I
, Blanco M
, Olmedilla Y
, Lopez A
, Vélez M D L Á
, Ágreda J
, Monereo S
To read results and conclusion, please login ...
Further abstracts you may be interested in